{"log_id": 4669163904117859611, "direction": 0, "words_result_num": 29, "words_result": [{"probability": {"variance": 3e-06, "average": 0.998888, "min": 0.990932}, "location": {"width": 996, "top": 140, "height": 45, "left": 111}, "words": "良反应,其药效与年龄小于60岁的患者无明显差异。对于70岁以上的患者,建议根据临床情"}, {"probability": {"variance": 0, "average": 0.999648, "min": 0.997828}, "location": {"width": 589, "top": 200, "height": 39, "left": 110}, "words": "况和实验室检查指标在医师指导下慎用和调整用药剂量"}, {"probability": {"variance": 1.7e-05, "average": 0.994751, "min": 0.988172}, "location": {"width": 183, "top": 247, "height": 34, "left": 118}, "words": "【药物相互作用】"}, {"probability": {"variance": 9e-06, "average": 0.998625, "min": 0.986882}, "location": {"width": 421, "top": 294, "height": 37, "left": 159}, "words": "本品尚未进行正式的药物相互作用研究"}, {"probability": {"variance": 0.00025, "average": 0.993068, "min": 0.92561}, "location": {"width": 469, "top": 343, "height": 34, "left": 163}, "words": "CYP3A4抑制剂和诱导剂对阿帕替尼的影响"}, {"probability": {"variance": 0.000418, "average": 0.988962, "min": 0.907971}, "location": {"width": 946, "top": 384, "height": 44, "left": 161}, "words": "体外代谢酶研究表明,阿帕替尼主要由CYP3A4代谢,其次经CYP2D6、CYP2C9和CYP2E1"}, {"probability": {"variance": 1.4e-05, "average": 0.997844, "min": 0.982054}, "location": {"width": 994, "top": 434, "height": 41, "left": 112}, "words": "代谢。阿帕替尼与CYP3A4的强抑制剂(伊曲康唑、克拉霉素、伏立康唑、泰利霉素、沙奎"}, {"probability": {"variance": 3e-06, "average": 0.998659, "min": 0.992055}, "location": {"width": 993, "top": 481, "height": 43, "left": 112}, "words": "那韦、利托那韦等)同时应用时,可能会增加阿帕替尼的血浆浓度;与CYP3A4的诱导剂(地"}, {"probability": {"variance": 0.001534, "average": 0.992659, "min": 0.745156}, "location": {"width": 993, "top": 529, "height": 43, "left": 114}, "words": "塞米松、苯妥英、卡马西乎、利福平、苯巴比妥、利福喷汀等)同时应用时,可能减低阿帕替"}, {"probability": {"variance": 0.001258, "average": 0.993044, "min": 0.76625}, "location": {"width": 992, "top": 578, "height": 42, "left": 115}, "words": "尼的血浆浓度。当需与其他药物联用时,建议选择可替代的对CYP3A4酶无抑制或无诱导的"}, {"probability": {"variance": 7e-06, "average": 0.998406, "min": 0.98897}, "location": {"width": 994, "top": 627, "height": 41, "left": 113}, "words": "药物,如果必须与CYP3A4酶强抑制剂或诱导剂同时应用,需要结合临床观察考虑是否进行"}, {"probability": {"variance": 0.000181, "average": 0.993075, "min": 0.966199}, "location": {"width": 180, "top": 666, "height": 51, "left": 113}, "words": "剂量调整。"}, {"probability": {"variance": 6e-06, "average": 0.998369, "min": 0.990916}, "location": {"width": 299, "top": 728, "height": 33, "left": 163}, "words": "阿帕替尼对其他药物的影响"}, {"probability": {"variance": 0.004104, "average": 0.980309, "min": 0.5894}, "location": {"width": 944, "top": 768, "height": 42, "left": 164}, "words": "体外研究表明,阿帕替尼对CYP3A4和CYP2C9有较强的抑制作用(IC50<1μM),因此"}, {"probability": {"variance": 0.000437, "average": 0.995345, "min": 0.862058}, "location": {"width": 990, "top": 815, "height": 42, "left": 117}, "words": "治疗期间应慎与主要经CYP3A4代谢的药物同时应用,如钙离子拮抗剂尼索地平和乐卡地平"}, {"probability": {"variance": 0.001604, "average": 0.98707, "min": 0.779999}, "location": {"width": 992, "top": 861, "height": 44, "left": 118}, "words": "等、HMG-CoA还原酶抑制剂辛伐他汀和洛伐他汀以及咪达唑仑等药物,慎与经CYP2C9代谢"}, {"probability": {"variance": 4.4e-05, "average": 0.996472, "min": 0.972381}, "location": {"width": 784, "top": 911, "height": 41, "left": 118}, "words": "的药物同时应用,如华法林、苯妥英、某些磺酰脲类降糖药如格列本脲等"}, {"probability": {"variance": 4e-06, "average": 0.99888, "min": 0.9919}, "location": {"width": 323, "top": 963, "height": 36, "left": 165}, "words": "引起心脏QT间期延长的药物"}, {"probability": {"variance": 1.6e-05, "average": 0.998501, "min": 0.981957}, "location": {"width": 946, "top": 1004, "height": 44, "left": 166}, "words": "由于同类药物在临床上有延长QT间期的毒副作用,本品临床研究观察到QT间期延长的"}, {"probability": {"variance": 8.3e-05, "average": 0.995161, "min": 0.958261}, "location": {"width": 993, "top": 1053, "height": 42, "left": 119}, "words": "发生率为0.57%(1/176)。因此在服用期间应慎用延长QT间期的药物,并在用药期间严密监"}, {"probability": {"variance": 1e-06, "average": 0.998597, "min": 0.997007}, "location": {"width": 98, "top": 1113, "height": 28, "left": 118}, "words": "测心电图"}, {"probability": {"variance": 9e-06, "average": 0.997245, "min": 0.990548}, "location": {"width": 323, "top": 1155, "height": 34, "left": 158}, "words": "其他对肝肾功能有影响的药物"}, {"probability": {"variance": 6e-06, "average": 0.998476, "min": 0.987762}, "location": {"width": 905, "top": 1194, "height": 45, "left": 159}, "words": "服用本品期间应慎用其他对肝肾功能有影响的药物,并在用药期间严密监测肝肾功能"}, {"probability": {"variance": 1.5e-05, "average": 0.995912, "min": 0.990307}, "location": {"width": 132, "top": 1255, "height": 29, "left": 129}, "words": "【药物过量"}, {"probability": {"variance": 0.000115, "average": 0.996409, "min": 0.937994}, "location": {"width": 941, "top": 1290, "height": 44, "left": 172}, "words": "目前尚不清楚过量服用阿帕替尼可能产生的症状,也没有针对服用过量阿帕替尼的特异疗"}, {"probability": {"variance": 0.008752, "average": 0.970485, "min": 0.435588}, "location": {"width": 996, "top": 1339, "height": 45, "left": 119}, "words": "法。在本品期临床研究中,部分患者服用阿帕替尼的最高剂量达10mg/天,在此剂量下观"}, {"probability": {"variance": 3e-06, "average": 0.998491, "min": 0.994505}, "location": {"width": 607, "top": 1392, "height": 40, "left": 122}, "words": "察到的不良反应主要为34级血压升高和3级手足综合征"}, {"probability": {"variance": 0.003173, "average": 0.989287, "min": 0.665753}, "location": {"width": 832, "top": 1436, "height": 45, "left": 171}, "words": "如怀疑服用药物过量,则应停药并对患者进行密切观察和给予相应的支持治疗"}, {"probability": {"variance": 7e-06, "average": 0.997488, "min": 0.992659}, "location": {"width": 133, "top": 1508, "height": 31, "left": 127}, "words": "【临床研究】"}], "language": 3}